Table 3.
Agreement between ER, PR and HER2 status from primary and recurrent samples
| ER status | K | PR status | K | HER2 Status | K | |
|---|---|---|---|---|---|---|
| (ASE) | (ASE) | (ASE) | ||||
| Agreement between HR and HER2 status from primary and recurrent research samples | ||||||
| Total (N) | 94 | 95 | 94 | |||
| Agreement, N (%) | ||||||
| Yes | 77 (81.9) | 0.628 | 69 (72.6) | 0.440 | 85 (90.4) | 0.784 |
| No | 17 (18.1) | (0.079) | 26 (27.4) | (0.086) | 9 (9.6) | (0.067) |
| + to − | 14 (14.9) | 22 (23.2) | 9 (9.6) | |||
| − to + | 3 (3.2) | 4 (4.2) | 0 (0) | |||
| Agreement before any treatment | ||||||
| Total (N) | 16 | 16 | 16 | |||
| Agreement, N (%) | ||||||
| Yes | 15 (93.7) | 0.875 (0.120) | 13 (81.3) | 0.586 (0.211) | 15 (93.7) | 0.875 (0.120) |
| No | 1 (6.3) | 3 (18.8) | 1 (6.3) | |||
| + to − | 1 (6.3) | 2 (12.5) | 1 (6.3) | |||
| − to + | 0 (0) | 1 (6.3) | 0 (0) | |||
| Agreement after treatment | ||||||
| Total (N) | 78 | 79 | 78 | |||
| Agreement, N (%) | ||||||
| Yes | 62 (79.5) | 0.569 (0.092) | 56 (70.9) | 0.414 (0.093) | 70 (89.7) | 0.750 (0.081) |
| No | 16 (20.5) | 23 (29.1) | 8 (10.3) | |||
| + to − | 13 (16.7) | 20 (25.3) | 8 (10.3) | |||
| − to + | 3 (3.8) | 3 (3.8) | 0 (0) | |||
Data was not available in a limited number of samples due to: (1) unknown information in the metastatic setting, (2) research biopsy performed at time of diagnosis. + to −: change from positive to negative marker; − to +: change from negative to positive marker
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor 2